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Supplemental Figure S1
Figure S1: OPA1 deacetylation is SIRT3 specific. (A) IB analysis of WCL and OPA1
IPed from WT and SIRT3-KO MEFs treated with (+) or without (-) n-acetyl cysteine
(NAC). (B) IB showing endogenous OPA1 binding to HA-SIRT3 IPed from SIRT3
transgenic hearts (Tg-HA.SIRT3). The gap between the lanes is due to omission of the
marker lane from the image. All lanes are from the same western blot and same
exposure.
A.
0
500
1000
1500
2000
2500
W
T
 O
P
A
C
o
n
tr
o
l
W
T
O
P
A
_
H
2
O
2
W
T
 O
P
A
S
IR
T
3
_
H
2
O
2
N
u
ll 
O
P
A
C
o
n
tr
o
l
N
u
ll
O
P
A
_
H
2
O
2
N
u
ll 
O
P
A
S
IR
T
3
_
H
2
O
2
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 
In
te
n
s
it
y
 (
R
O
S
)
P=0.001P=1.5x10-6
P=1.4x10-5
B.
Supplemental Figure S2
Figure S2. SIRT3 requires OPA1 to alter mitochondrial morphology and function: (A) Effect of
over-expression of SIRT3 (Ad.SIRT3) on mitochondrial morphology of immortalized OPA1 MEFs
(lower panels). Mitochondria are visualized by over-expressing either mitoGFP (Ad.Mito-GFP,
green) or SIRT3 (Ad.SIRT3) and by immunostaining for SIRT3 (red). In the lower left panel, inset
shows intermediate morphology of mitochondria and arrow indicates fused perinuclear
mitochondria. OPA1 WT MEFs serve as a positive control. Scale bar: 5µm (B) Bar graphs showing
quantification of the mean fluorescence intensity (representing ROS levels) for immortalized OPA1
WT and null MEFs treated with H2O2 (200 µM) and stained with CM-H2DCFDA. Values are mean ±
SEM, n = 5. P values (two-tailed paired t-test) denote statistical significance between indicated
groups.
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OPA1 AA Observed Mr(expt) Mr(calc) Delta Da Miss Sequence Intensity MS Scan RT sec Charge
925 - 941 689.3044 2064.89 2064.23 0.6609 4 K.VKAcLLTGKAcRVQLAEDLKKAc.V  3 Acetyl (K) (K926Ac, K931Ac, K941Ac) (Ions score 30) 110191.86 4817 2244.16 3+
Ac Intensity 110191.86
932 - 941 400.5747 1198.7 1198.7 -0.001 2 K.RVQLAEDLKK.V  (Ions score 45) 36038.53 2361 1360.76 3+
932 - 941 409.9068 1226.7 1226.7 0.0004 2 K.RVQLAEDLKK.V  Formyl (N-term) (Ions score 56) 31633.94 3704 1843.44 3+
933 - 940 458.2601 914.506 914.507 -0.0017 0 R.VQLAEDLK.K  (Ions score 33) 59797.11 3569 1791.84 2+
933 - 941 522.3082 1042.6 1042.6 -0.0003 1 R.VQLAEDLKK.V  (Ions score 45) 106105.16 2683 1469.51 2+
933 - 941 536.3057 1070.6 1070.6 -0.0003 1 R.VQLAEDLKK.V  Formyl (N-term) (Ions score 21) 32042.7617 5108 2349.26 2+
Non-Ac Intensity 265617.49
SIRT3-KO-OPA1 Total Ion Intensity 375809.35
Relative Stoichiometry of OPA1_MUS K926Ac, K931Ac, K941Ac 29.32%
(Ac/(Non-Ac+Ac))
Match to: OPA1_MOUSE Score: 715
Dynamin-like 120 kDa protein, mitochondrial OS=Mus musculus GN=Opa1 PE=1 SV=1
Found in search of o63_11jun29_07_uc_90min_293opa.mgf
SIRT3-KO-OPA1 926KAc and 931KAc
Figure S3. OPA1 is acetylated at K926 and K931 in the GTPase effector domain (GED):
(A) A representative tandem mass spectrum of tryptic peptide of OPA1 from SIRT3-KO
heart depicting K926 and K931 acetylation. Since the acetylated K941 was the most C-
terminal lysine in the tryptic peptide, it was an artifact (29). (B) Schematic representation
showing locations of acetylated K926/K931 in the C-terminal GED region of the OPA1
protein. (C) Relative stoichiometry of acetylated peptides for SIRT3-KO cardiac OPA1.
PCAF-mediated OPA1 acetylation sites
Site Peptide Charge m/z Scans Intensity Stoichiometry
K214
Non-Ac Mass EKIDQLQEELLHTQLK 3+ 665.6948 5946-6048 280000
Ac Mass EKIDQLQEELLHTQLK 3+ 668.6966 6552-6727 9999 3.45%
K253, K261
Non-Ac Mass LVLQKDDKGIHHR 3+ 520.29 1052-1357 8260
Ac Mass DDKGIHHRKLK 3+ 476.58 5555-5655 23800 74.24%
K926, K931  
Non-Ac Mass KIKLLTGKR not seen NA NA 0
Ac Mass KIKLLTGKR 3+ 381.19 1291-1629 72900 100%
PCAF-mediated OPA1 Ac-926K/931K Peptide
Supplemental Figure S4
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B.
Figure S4: PCAF also acetylates OPA1-K926/931 residues in vitro: (A) Relative
stoichiometry for acetylated peptides derived from human myc.OPA1 acetylated in
vitro by PCAF. (B) Tandem mass spectrum for acetylated 926-931K peptide derived
as described in A.
A.
Supplemental Figure S5
0
0.2
0.4
0.6
0.8
1
1.2
wt null rWT r926R r926Q r931R r931Q
N
o
rm
a
liz
e
d
 m
tD
N
A
 c
o
p
y
 
n
u
m
b
e
r 
re
la
ti
v
e
 t
o
 W
T
NS
NS
*
*
*
OPA1 Null MEF Stable
C.
B.
*
NS
0
0.2
0.4
0.6
0.8
1
1.2
N
o
rm
a
liz
e
d
 m
tD
N
A
 c
o
p
y
 n
u
m
b
e
r 
re
la
ti
v
e
 t
o
 W
T
WT
OPA Null MEFs +
Vector WT(K)-OPA dmR-OPA dmQ-OPA 
*
Figure S5: Mitochondrial copy number is rescued with expression of deacetylation-mimetic
OPA1 isoform in OPA1 null cells: (A) Estimated mitochondrial DNA (mtDNA) copy number
normalized per nuclear genome for indicated OPA1 stable mutant is graphically represented
(means ± SEM, n = 3), relative to that for immortalized wild-type OPA1 (wt) MEFs. Statistical
significance is calculated by comparing the copy number for mutants versus OPA1 null MEFs.
While rWT, r926R and r931R show significant recovery in mtDNA copy the Q mutants show
statistically insignificant (NS) increase in copy number in comparison with OPA1-null MEFs. *
indicates p<0.001(two-tailed paired t-test). (B) Bar diagram depicting recovery of
mitochondrial copy number for OPA1 null MEFs transiently over-expressing myc.OPA1-
926/931R (dmR) double mutant protein as opposed to the dmQ mutant. WT-myc.OPA1 (K)
expressing cells served as a positive control. Data represented as described in A. * indicates
p<0.05(two-tailed paired t-test, n=3). (C) IB showing expression level of indicated myc.OPA1
mutant expressed in OPA1 null MEFs.
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Figure S6: Cellular ROS levelws are significantly reduced with over-expression of
deacetylation mimetic OPA1 (dmR) in SIRT3-KO MEFs: (A) Graphical
representation showing of ROS levels for immortalized SIRT3-KO MEFs over-
expressed with myc.OPA1-926/931 R (dmR) or dmQ mutant or a vector and
challenged with H2O2 (200µM). * indicates significant reduction (p<0.001, n=3) in
ROS level for OPA1-dmR expressing MEFs, but not for the dmQ-mutant cells. (B) IB
showing expression level of indicated myc.OPA1 mutant expressed in immortalized
SIRT3-KO MEFs.
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Supplemental Figure 7
Figure S7. SIRT3 over-expression blocks doxorubicin-induced death of
cardiomyocytes: IB analysis of cell death markers for cardiomyocytes expressed
with SIRT3 or adenoviral (Ad.) vector and treated with two different doses of
doxorubicin. Note reduced induction of Bax, FasL and Bim after Dox treatment in
SIRT3 over-expressing cells, compared to Ad.vector expressing cells.
